Philips wins multiple clearances

A computed tomography scanner is an X-ray camera that builds cross-section images of the body, and radiation therapy teams use those images like a map before aiming cancer treatment. Philips said on April 22 that the U.S. Food and Drug Administration cleared three new systems in that workflow: Rembra CT, Rembra RT, and Areta RT. (philips.com) The clearance route was 510(k), the Food and Drug Administration pathway used when a device is shown to be substantially equivalent to one already on the market. Philips said the newly cleared systems are meant for frontline imaging and for radiation therapy planning, where hospitals need scans quickly and consistently. (fda.gov, biospace.com) The Food and Drug Administration database shows a Philips 510(k) decision dated March 23, 2026, for CT Rembra RT, CT Areta RT, and CT Rembra under submission K252992. The database lists the product code as JAK in radiology and the decision as substantially equivalent. (accessdata.fda.gov, accessdata.fda.gov) Philips had previewed the radiation oncology versions in September 2025 at the American Society for Radiation Oncology meeting, when the company said Rembra RT and Areta RT were still 510(k) pending and not yet for sale in the United States. It introduced the radiology-focused Rembra CT publicly in March 2026 at the European Congress of Radiology with the same pending status. (biospace.com, philips.com) That sequence matters for hospital buyers because a launch with “pending” status is a product preview, while a 510(k) clearance is the step that opens the U.S. market. Philips is pitching the cleared family around capacity and workflow, not just image quality, as imaging departments and cancer centers try to handle more scans with limited staff. (fda.gov, philips.com) For the radiology version, Philips said Rembra can produce up to 106 images per second and support throughput of up to 270 patients per day. The company also said the system has an 85-centimeter bore, the opening patients pass through, which it markets for trauma, bariatric imaging, and other hard-to-position cases. (philips.com, biospace.com) For cancer treatment planning, the task is different: teams are not just finding disease, they are outlining the tumor and nearby organs before radiation is delivered. Philips said Rembra RT and Areta RT are designed to make that planning step faster and more accurate with clearer images and workflow tools aimed at precision across the cancer care pathway. (philips.com, philips.com) The announcement also extends a busy April for Philips in computed tomography. On April 16, the company said the Food and Drug Administration cleared Verida, its detector-based spectral CT system, giving Philips two separate U.S. clearance announcements in the modality within a week. (biospace.com, philips.com) The immediate change is simple: Philips now has Food and Drug Administration-cleared U.S. versions of the Rembra family it had been showing as pending. The next test is whether hospitals and cancer centers translate those clearances into purchase orders. (philips.com, accessdata.fda.gov)